Degirmenci, M <br/><br/>
Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer.  [electronic resource] 

 -  Medical oncology (Northwood, London, England)  Sep 2010 
 - 585-91 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1559-131X 
<br/><br/><label>Standard No.: </label>10.1007/s12032-009-9253-5  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenocarcinoma--drug therapy<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Angiogenesis Inhibitors--administration & dosage<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Bevacizumab<br/>Camptothecin--administration & dosage<br/>Capecitabine<br/>Colonic Neoplasms--drug therapy<br/>Deoxycytidine--administration & dosage<br/>Disease-Free Survival<br/>Fatigue--chemically induced<br/>Female<br/>Fluorouracil--administration & dosage<br/>Gastrointestinal Diseases--chemically induced<br/>Hematologic Diseases--chemically induced<br/>Humans<br/>Hypertension--chemically induced<br/>Irinotecan<br/>Kaplan-Meier Estimate<br/>Male<br/>Middle Aged<br/>Neoplasm Proteins--antagonists & inhibitors<br/>Rectal Neoplasms--drug therapy<br/>Retrospective Studies<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors